Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Design Therapeutics, Inc. (DSGN) had Return on Tangible Equity of -32.84% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-69.79M |
|
-- |
|
-- |
|
$79.47M |
|
$-79.47M |
|
$9.68M |
|
$-69.79M |
|
$-69.79M |
|
$-69.79M |
|
$-69.79M |
|
$-69.79M |
|
$-69.79M |
|
$-79.47M |
|
$-82.10M |
|
57.33M |
|
57.33M |
|
$-1.22 |
|
$-1.22 |
|
| Balance Sheet Financials | |
$223.78M |
|
$0.98M |
|
$2.42M |
|
$226.20M |
|
$13.05M |
|
-- |
|
$0.65M |
|
$13.70M |
|
$212.50M |
|
$212.50M |
|
$212.50M |
|
60.40M |
|
| Cash Flow Statement Financials | |
$-54.36M |
|
$22.91M |
|
$25.74M |
|
$22.56M |
|
$16.86M |
|
$-5.71M |
|
$14.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-54.55M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-32.84% |
|
|
Return on Tangible Equity |
-32.84% |
-30.85% |
|
-32.84% |
|
$3.52 |
|
$-0.95 |
|
$-0.95 |
|